import { initDb } from "./db";

export async function seed() {
  const db = await initDb();

  // Skip seeding if data already exists
  const existing = await db.execute("SELECT COUNT(*) as count FROM blog_posts");
  const count = Number(existing.rows[0].count);
  if (count > 0) {
    console.log("Database already has data, skipping seed.");
    return;
  }

  // Clear existing data
  await db.execute("DELETE FROM pages");
  await db.execute("DELETE FROM blog_posts");
  await db.execute("DELETE FROM faqs");
  await db.execute("DELETE FROM products");
  await db.execute("DELETE FROM site_settings");

  // ── Pages ──────────────────────────────────────────────────────

  await db.execute({
    sql: "INSERT INTO pages (slug, title, meta_description, content) VALUES (?, ?, ?, ?)",
    args: [
      "home",
      "NutraGLP — Natural GLP-1 Activation",
      "Slim SHOT is a daily liquid formula that activates your body's own GLP-1 production. No needle. No prescription. No catch. $149/mo.",
      JSON.stringify({
        hero: {
          kicker: "Natural GLP-1 Activation",
          headline: "No needle. No prescription.",
          headlineAccent: "No catch.",
          description:
            "Slim SHOT is a daily liquid formula that activates your body's own GLP-1 production. Clinically studied compounds. Patent-pending nanoemulsion delivery. $149/mo.",
          scienceLink: "Read the Science",
        },
        proofBar: [
          { value: "100%", label: "GRAS Certified" },
          { value: "0", label: "Injections" },
          { value: "$149", label: "Per Month" },
          { value: "No Rx", label: "Required" },
        ],
        problem: {
          kicker: "The Problem",
          headline: "Forty-two million prescriptions. Same three trade-offs.",
          paragraphs: [
            "GLP-1 drugs work. The data is clear. But the delivery model forces a choice most people shouldn't have to make: weekly injections with significant side effects, $1,000+ monthly costs without insurance, or a waitlist that stretches past the point of motivation.",
            "Meanwhile, the supplement aisle offers the opposite problem. Dozens of products claiming metabolic support, built on single-compound formulas with minimal bioavailability and no real mechanism of action.",
            "The space between pharmaceutical efficacy and supplement accessibility is where metabolic health actually lives. That's where we built NutraGLP.",
          ],
          boldSentence:
            "The space between pharmaceutical efficacy and supplement accessibility is where metabolic health actually lives.",
        },
        mechanism: {
          kicker: "How It Works",
          headline: "Your body already makes GLP-1.",
          headlineLine2: "NutraGLP helps it make more.",
          description:
            "GLP-1 drugs work by injecting synthetic hormones. NutraGLP takes a different approach: a drinkable liquid that amplifies your body's natural GLP-1 production while inhibiting the enzyme that breaks it down. Three steps, one daily dose.",
          steps: [
            {
              num: "1",
              title: "Activate",
              text: "Four GRAS-certified active systems stimulate your body\u2019s own GLP-1 and GIP production in the gut through AMPK activation, GPR120 signaling, and insulin receptor sensitization. The same hormones the drugs target, produced naturally.",
            },
            {
              num: "2",
              title: "Protect",
              text: "Natural DPP-4 inhibitors extend the life of your GLP-1 before it breaks down. More active hormone. Longer metabolic window. No synthetic peptides.",
            },
            {
              num: "3",
              title: "Deliver",
              text: "Most oral supplements fail because the body can\u2019t absorb them. Our patent-pending nanoemulsion technology solves this. High bioavailability. Every dose, every day.",
            },
          ],
        },
        personas: {
          kicker: "Who This Is For",
          headline: "Three reasons people find us.",
          description:
            "Different starting points. Same gap in the market. If one of these sounds like your story, Slim SHOT was built for you.",
          cards: [
            {
              label: "The needle question",
              headline:
                "I want the results. I don\u2019t want the injection.",
              body: "You\u2019ve read about GLP-1 drugs. Maybe your doctor mentioned them. But a weekly self-injection with nausea, gastroparesis risk, and no clear end date isn\u2019t the answer you were looking for. Slim SHOT is a daily liquid you drink. Same biological pathway, activated naturally. No needle. No clinic visit. No side effects you have to Google at 2am.",
            },
            {
              label: "The cost question",
              headline:
                "I can\u2019t justify $1,600 a month. I still need something that works.",
              body: "Ozempic without insurance runs $800\u2013$1,600/month. Compounded versions are legally uncertain. The supplement aisle is noise. Slim SHOT is $149/mo, ships to your door, and uses patent-pending nanoemulsion technology to actually deliver what most supplements can\u2019t. Real mechanism of action. Real bioavailability. Price that doesn\u2019t require a second income.",
            },
            {
              label: "The performance question",
              headline:
                "I\u2019m not trying to lose weight. I\u2019m trying to optimize.",
              body: "You train. You eat well. You want metabolic efficiency without the muscle wasting that comes with synthetic GLP-1 agonists at higher doses. Slim SHOT activates 13 complementary metabolic pathways while preserving lean mass. It\u2019s built for people who want precision, not a blunt instrument. Metabolic health as a performance input, not a medical intervention.",
            },
          ],
        },
        contrast: {
          kicker: "A Different Category",
          headline: "What changes when you don't need a prescription.",
          them: [
            "Weekly self-injection",
            "$800\u2013$1,600/month without insurance",
            "Nausea, vomiting, gastroparesis risk",
            "Provider visit + prior authorization",
            "Single synthetic mechanism",
            "Muscle loss concerns at higher doses",
          ],
          us: [
            "Daily drinkable liquid nanoemulsion",
            "Fraction of prescription cost",
            "GRAS-certified, clinically studied compounds",
            "No prescription required",
            "13 complementary metabolic pathways",
            "Designed to preserve lean mass",
          ],
        },
        science: {
          kicker: "The Science",
          headline: "Built on published research. Not marketing claims.",
          paragraphs: [
            "Every compound in the NutraGLP formula is backed by peer-reviewed studies demonstrating metabolic activity. The nanoemulsion delivery system addresses the bioavailability gap that limits most oral nutraceuticals, ensuring the compounds reach their target pathways at therapeutic-relevant concentrations.",
            "We chose not to build a single-mechanism product. GLP-1 signaling is part of a larger metabolic system that includes insulin sensitivity, appetite regulation, glucose uptake, and lipid metabolism. NutraGLP engages 13 distinct pathways because metabolic health isn't a single-variable problem.",
            "Patent-pending formulation. GRAS-certified compounds. Third-party tested. Designed for the regulatory framework that actually exists.",
          ],
        },
        latestResearch: {
          kicker: "Research & Insights",
          headline: "The evidence behind the formula",
        },
        cta: {
          headline: "Ready to try a different approach?",
          description:
            "Join the waitlist for early access and pricing. Slim SHOT ships direct. $149/mo. No prescription. No commitment.",
        },
      }),
    ],
  });

  // ── Blog Posts ─────────────────────────────────────────────────

  const blogSql = `INSERT INTO blog_posts (slug, title, description, date, read_time, tag, gradient, sections, related_slugs) VALUES (?, ?, ?, ?, ?, ?, ?, ?, ?)`;

  await db.execute({
    sql: blogSql,
    args: [
      "natural-glp1-activation",
      "Natural GLP-1 Activation: What the Research Shows",
      "AMPK activation in intestinal L-cells stimulates endogenous GLP-1 secretion. A review of the clinical evidence behind natural incretin production and what it means for metabolic support.",
      "2026-02-20",
      "8 min",
      "Compound Science",
      "from-forest-deep to-forest",
      JSON.stringify([
        {
          heading: "The AMPK pathway and GLP-1 production",
          body: [
            "AMP-activated protein kinase (AMPK) is a master regulator of cellular energy metabolism. When activated in intestinal L-cells, AMPK triggers a signaling cascade that increases the transcription and secretion of GLP-1 (glucagon-like peptide-1), the same incretin hormone targeted by pharmaceutical drugs like semaglutide and tirzepatide.",
            "This pathway is distinct from nutrient-stimulated GLP-1 release. AMPK-driven secretion can amplify GLP-1 output beyond what food intake alone produces, opening a non-pharmaceutical route to incretin modulation.",
          ],
        },
        {
          heading: "How natural compounds stimulate GLP-1 secretion",
          body: [
            "GLP-1 is an incretin hormone secreted by L-cells in the small intestine after food intake. It signals the brain to reduce appetite, slows gastric emptying, and stimulates glucose-dependent insulin secretion. The pharmaceutical GLP-1 drug class works by injecting synthetic versions of this hormone at supraphysiological doses.",
            "Certain GRAS-certified compounds activate AMPK in intestinal L-cells, triggering endogenous GLP-1 secretion through the body's own production machinery. Multiple randomized controlled trials have demonstrated statistically significant increases in postprandial GLP-1 levels with AMPK-activating compounds compared to placebo.",
            "Parallel pathways contribute to the effect. GPR120 receptor activation and insulin receptor sensitization each stimulate GLP-1 through distinct but complementary mechanisms. The combination addresses multiple nodes on the same biological pathway.",
          ],
        },
        {
          heading: "Clinical evidence for natural metabolic modulation",
          body: [
            "AMPK-activating compounds have a robust body of clinical evidence supporting their effects on metabolic parameters. Meta-analyses of randomized controlled trials have found significant effects on fasting blood glucose, HbA1c, total cholesterol, LDL cholesterol, and triglycerides.",
            "The GLP-1-specific effects are a more recent area of investigation. The identification of AMPK-mediated GLP-1 secretion as a primary mechanism has reframed these metabolic effects within the incretin pathway, connecting them to the same biological system targeted by the GLP-1 drug class.",
            "This does not mean the effects are equivalent to pharmaceutical GLP-1 agonists. The magnitude is different. The mechanism is different. But the pathway is the same, and the clinical evidence supporting the upstream activation of that pathway is real and growing.",
          ],
        },
        {
          heading: "Bioavailability: the limiting factor",
          body: [
            "The primary challenge with oral metabolic compounds is bioavailability. Many AMPK activators have absolute oral bioavailability below 10%, meaning the majority of an ingested dose never reaches systemic circulation. Poor absorption across the intestinal membrane and extensive first-pass hepatic metabolism are the main bottlenecks.",
            "This low bioavailability is why standard oral formats, despite containing adequate doses, produce inconsistent results. A compound may show strong effects in controlled trials where delivery is optimized, but in a standard capsule or tablet, most of the active compound is lost before reaching its target pathways.",
            "Nanoemulsion delivery systems address this limitation by encapsulating active compounds in lipid-based nanoparticles (20-200nm). This increases surface area for absorption, protects compounds from enzymatic degradation in the GI tract, and enhances transcellular transport across the intestinal epithelium.",
          ],
        },
        {
          heading: "Safety and drug interaction considerations",
          body: [
            "The compounds used in natural GLP-1 activation formulas carry GRAS (Generally Recognized as Safe) status and have well-documented safety profiles at standard dosages. The most common side effects are mild gastrointestinal symptoms, particularly when initiating a new regimen.",
            "The primary safety concern is drug interactions. Some AMPK-activating compounds inhibit cytochrome P450 enzymes (CYP2D6, CYP2C9, CYP3A4), which metabolize many prescription medications. They can also potentiate the effects of blood sugar-lowering drugs.",
            "Anyone taking prescription medication should consult their healthcare provider before starting any new regimen. This applies to any compound with documented metabolic activity, regardless of its regulatory classification.",
          ],
        },
      ]),
      JSON.stringify(["nanoemulsion-vs-capsules", "endogenous-vs-exogenous-glp1"]),
    ],
  });

  await db.execute({
    sql: blogSql,
    args: [
      "nanoemulsion-vs-capsules",
      "Nanoemulsion vs. Capsules: Why Delivery Format Matters",
      "Most oral supplements fail at absorption. Nanoemulsion technology encapsulates active compounds in lipid-based nanoparticles, dramatically improving bioavailability compared to standard capsules and tablets.",
      "2026-02-14",
      "7 min",
      "Delivery Technology",
      "from-forest to-forest-mid",
      JSON.stringify([
        {
          heading: "The bioavailability problem in oral supplements",
          body: [
            "Bioavailability refers to the proportion of an ingested substance that reaches systemic circulation in an active form. For most oral supplements, this number is surprisingly low. Compounds degrade in stomach acid, fail to cross the intestinal membrane efficiently, or are metabolized by the liver before reaching their target tissues.",
            "This creates a gap between what clinical research demonstrates and what consumers experience. A compound may show strong effects in a controlled trial where dosing, timing, and formulation are optimized, but when the same compound is compressed into a standard capsule or tablet and sold over the counter, the results are often inconsistent or absent.",
            "The supplement industry has historically addressed this problem by increasing dosage. If bioavailability is 5%, increase the dose twentyfold. This approach has obvious limitations: larger pills, more excipients, greater GI side effects, and a ceiling on what can be practically delivered in a single dose.",
          ],
        },
        {
          heading: "What is nanoemulsion technology?",
          body: [
            "A nanoemulsion is a colloidal dispersion of two immiscible liquids (typically oil and water) stabilized by surfactants, with droplet sizes in the 20-200 nanometer range. In the context of supplement delivery, it means encapsulating active compounds in lipid-based nanoparticles that are small enough to be readily absorbed across the intestinal epithelium.",
            "The key advantages over standard oral formats are threefold. First, the dramatically increased surface area (a function of particle size) means more compound is exposed to absorptive surfaces. Second, the lipid coating protects the compound from enzymatic degradation in the GI tract. Third, lipid-based nanoparticles can exploit natural lipid absorption pathways to enhance transcellular transport.",
            "Unlike some nanotechnology applications that require complex manufacturing processes, nanoemulsions can be produced using high-pressure homogenization or microfluidization, making them scalable for commercial production while maintaining consistent particle size distribution.",
          ],
        },
        {
          heading: "Nanoemulsion vs. liposomal delivery",
          body: [
            "Liposomal delivery is another lipid-based approach that has gained popularity in the supplement market. Liposomes are spherical vesicles with a phospholipid bilayer surrounding an aqueous core. They can encapsulate both hydrophilic (water-soluble) and hydrophobic (fat-soluble) compounds.",
            "Nanoemulsions and liposomes share the principle of lipid-based encapsulation but differ in structure and performance characteristics. Nanoemulsions are thermodynamically stable oil-in-water (or water-in-oil) systems, while liposomes are metastable structures that can fuse, aggregate, or leak over time. This gives nanoemulsions a practical advantage in shelf stability and batch-to-batch consistency.",
            "For the specific compounds used in GLP-1 activation formulas, nanoemulsion was selected over liposomal delivery because of superior physical stability, more consistent particle size distribution, and better compatibility with the hydrophobic nature of the active compounds.",
          ],
        },
        {
          heading: "Why the liquid format is required",
          body: [
            "A common question about nanoemulsion supplements is why they cannot be delivered as a capsule or tablet. The answer is structural. Compressing a nanoemulsion into a dry format would destroy the nanoparticle architecture that makes it effective. The lipid-based droplets require an aqueous phase to maintain their size, stability, and surface properties.",
            "The liquid format also eliminates the dissolution step required by tablets and capsules. When a standard supplement is swallowed, it must first disintegrate, then dissolve, before any absorption can occur. This process adds time and introduces variability. A liquid nanoemulsion bypasses disintegration and dissolution entirely, presenting the active compounds in a pre-solubilized, immediately absorbable form.",
          ],
        },
        {
          heading: "Implications for supplement efficacy",
          body: [
            "The difference between a standard capsule and a nanoemulsion delivery system is not incremental. Published research on nanoemulsion-enhanced bioavailability reports improvements ranging from 3x to 10x or more, depending on the specific compound and formulation parameters.",
            "For AMPK-activating compounds where standard oral bioavailability is below 10%, even a modest improvement in delivery efficiency can shift the clinical effect profile significantly. The goal is not to increase the dose but to ensure a larger proportion of each dose reaches its intended metabolic target.",
            "This is why delivery format is not a marketing detail. It is the primary technical variable determining whether a formula produces the effects its compound profile suggests it should.",
          ],
        },
      ]),
      JSON.stringify(["natural-glp1-activation", "natural-dpp4-inhibition"]),
    ],
  });

  await db.execute({
    sql: blogSql,
    args: [
      "natural-dpp4-inhibition",
      "Natural DPP-4 Inhibition: Extending Your Body's Own GLP-1",
      "DPP-4 breaks down GLP-1 within minutes of production. Natural compounds with demonstrated DPP-4 inhibitory activity can extend the half-life of endogenous incretins.",
      "2026-02-07",
      "6 min",
      "Mechanism",
      "from-forest-mid to-forest-deep",
      JSON.stringify([
        {
          heading: "What is DPP-4 and why does it matter?",
          body: [
            "Dipeptidyl peptidase-4 (DPP-4) is a serine protease enzyme that cleaves incretin hormones, including GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). DPP-4 is the primary reason endogenous GLP-1 has a half-life of only about 2 minutes. The hormone is produced, exerts a brief effect, and is rapidly degraded.",
            "This rapid degradation is a normal physiological process. It prevents sustained hormonal signaling from a single meal and maintains tight control over insulin secretion and appetite regulation. But it also means that any strategy to boost natural GLP-1 production faces a clearance problem: even if you increase GLP-1 secretion, the additional hormone is broken down almost as fast as it is produced.",
            "Pharmaceutical companies recognized this limitation early. The DPP-4 inhibitor drug class (sitagliptin, saxagliptin, linagliptin) was developed specifically to slow GLP-1 degradation, extending the effective window of endogenously produced incretins. These drugs are widely prescribed for type 2 diabetes.",
          ],
        },
        {
          heading: "Natural compounds with DPP-4 inhibitory activity",
          body: [
            "Research has identified several naturally occurring compounds with demonstrated DPP-4 inhibitory activity in vitro. These include certain flavonoids, polyphenols, and bioactive peptides derived from food sources.",
            "The mechanism is the same as pharmaceutical DPP-4 inhibitors: competitive or noncompetitive binding to the enzyme's active site, reducing its ability to cleave GLP-1 and GIP. The key difference is potency. Pharmaceutical DPP-4 inhibitors are designed for high-affinity binding and near-complete enzyme inhibition. Natural compounds typically show moderate inhibition at achievable plasma concentrations.",
            "Moderate inhibition is not clinically irrelevant. A partial reduction in DPP-4 activity can meaningfully extend the functional half-life of GLP-1, particularly when combined with strategies that simultaneously increase GLP-1 production. The combination of increased production and reduced degradation creates a compounding effect on active GLP-1 levels.",
          ],
        },
        {
          heading: "The production-plus-protection strategy",
          body: [
            "The most effective approach to boosting endogenous incretin levels combines two mechanisms: stimulating production and inhibiting degradation. This is analogous to filling a bathtub while simultaneously partially plugging the drain.",
            "In the NutraGLP formula, four active systems stimulate GLP-1 and GIP production through distinct pathways: AMPK activation, insulin receptor sensitization, and GPR120 activation. Natural DPP-4 inhibitors then extend the half-life of the newly produced incretins by slowing enzymatic breakdown.",
            "Neither mechanism alone achieves the same result as the combination. Increasing production without addressing degradation results in a brief spike that DPP-4 quickly clears. Inhibiting DPP-4 without increasing production only extends the baseline level. The combination amplifies both the peak and duration of endogenous GLP-1 activity.",
          ],
        },
        {
          heading:
            "How natural DPP-4 inhibition differs from pharmaceutical DPP-4 inhibitors",
          body: [
            "Pharmaceutical DPP-4 inhibitors (gliptins) achieve 70-90% enzyme inhibition at therapeutic doses. Natural compounds typically achieve more modest inhibition levels. This difference in potency is significant and should not be understated.",
            "The trade-off is in the risk-benefit profile. Pharmaceutical DPP-4 inhibitors carry risks including pancreatitis, joint pain, and potential immunosuppressive effects related to DPP-4's role in immune function. Natural DPP-4 inhibitors, at the concentrations achievable through oral supplementation, are associated with fewer adverse effects.",
            "The appropriate framing is not that natural DPP-4 inhibition replaces pharmaceutical inhibition. It is that partial DPP-4 inhibition, combined with enhanced GLP-1 production, provides a complementary metabolic support strategy with a different risk-benefit profile than pharmaceutical intervention.",
          ],
        },
      ]),
      JSON.stringify(["endogenous-vs-exogenous-glp1", "natural-glp1-activation"]),
    ],
  });

  await db.execute({
    sql: blogSql,
    args: [
      "endogenous-vs-exogenous-glp1",
      "Endogenous vs. Exogenous GLP-1: Two Approaches to the Same Pathway",
      "Pharmaceutical GLP-1 drugs inject synthetic peptides. Endogenous activation amplifies hormones the gut already produces. Different mechanisms, different risk-benefit profiles, same biological target.",
      "2026-01-30",
      "9 min",
      "GLP-1 Fundamentals",
      "from-forest-deep via-forest to-forest-mid",
      JSON.stringify([
        {
          heading: "The GLP-1 pathway",
          body: [
            "GLP-1 (glucagon-like peptide-1) is an incretin hormone that plays a central role in glucose homeostasis, appetite regulation, and metabolic function. It is produced by L-cells in the distal small intestine and colon in response to nutrient intake. Once secreted, GLP-1 acts on receptors in the pancreas (stimulating insulin secretion), the brain (reducing appetite and food intake), and the GI tract (slowing gastric emptying).",
            "The discovery that GLP-1 receptor activation could produce significant weight loss transformed the pharmaceutical landscape. Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) have become among the most prescribed and discussed drugs in the world, generating tens of billions in annual revenue.",
            "What is sometimes lost in the conversation is that GLP-1 is not a pharmaceutical invention. It is an endogenous hormone. The drugs work by introducing synthetic versions of it at supraphysiological concentrations. The alternative approach, endogenous activation, works by amplifying the body's own production.",
          ],
        },
        {
          heading: "How exogenous GLP-1 drugs work",
          body: [
            "Exogenous GLP-1 receptor agonists (GLP-1 RAs) are synthetic peptides engineered to mimic natural GLP-1 while resisting degradation by the DPP-4 enzyme. Semaglutide, for example, has structural modifications that extend its half-life from 2 minutes (natural GLP-1) to approximately 7 days, enabling once-weekly dosing.",
            "These drugs achieve GLP-1 receptor activation at concentrations far above what the body produces naturally. This supraphysiological stimulation produces pronounced effects: significant appetite suppression, slowed gastric emptying, improved glycemic control, and in many patients, substantial weight loss (15-20% of body weight in clinical trials).",
            "The potency of exogenous GLP-1 is also the source of its side effect profile. Nausea, vomiting, diarrhea, and constipation are common, particularly during dose titration. More serious but less common concerns include pancreatitis, gallbladder disease, and reports of muscle mass loss accompanying fat loss. The long-term effects of sustained supraphysiological GLP-1 receptor activation are still being studied.",
          ],
        },
        {
          heading: "How endogenous GLP-1 activation works",
          body: [
            "Endogenous activation takes a fundamentally different approach. Rather than introducing synthetic peptides from outside the body, it aims to increase the production and extend the half-life of the GLP-1 your gut already makes.",
            "This involves two parallel strategies. First, stimulating L-cell secretion of GLP-1 through compounds that activate known production pathways, including AMPK activation, GPR120 receptor activation, and insulin receptor sensitization. Second, inhibiting DPP-4, the enzyme that degrades GLP-1, to extend the window each molecule of endogenous GLP-1 remains active.",
            "The endogenous approach works within the body's existing feedback mechanisms. Natural GLP-1 production is regulated by nutrient intake, hormonal feedback loops, and neural signaling. Amplifying this production increases the signal within the system's normal operating parameters, rather than overriding the system with external input.",
          ],
        },
        {
          heading: "Comparing the two approaches",
          body: [
            "The key distinction is concentration and control. Exogenous GLP-1 drugs deliver the hormone at concentrations many times higher than the body produces naturally, and the effect persists for days due to engineered resistance to degradation. Endogenous activation increases production and extends half-life within a range closer to the body's natural capacity.",
            "This means the exogenous approach is more powerful in absolute terms. The clinical data on semaglutide and tirzepatide show effects that no supplement can replicate. If maximizing weight loss is the sole objective and the risk-benefit analysis supports it, pharmaceutical GLP-1 drugs are the more potent tool.",
            "The endogenous approach offers a different value proposition. It is non-prescription, non-injectable, and works within physiological ranges. For individuals who do not qualify for or do not want pharmaceutical GLP-1 therapy, or who are looking for metabolic support rather than maximum pharmacological intervention, endogenous activation provides a complementary option.",
            "It is important to state clearly: endogenous GLP-1 activation is not a replacement for prescribed GLP-1 medication. The two approaches target the same pathway through different mechanisms with different magnitudes of effect. They occupy different positions on the intervention spectrum.",
          ],
        },
        {
          heading: "The bioavailability variable",
          body: [
            "One factor that has historically limited endogenous activation strategies is bioavailability. AMPK-activating compounds have strong clinical evidence for GLP-1 stimulation but poor oral absorption in standard formats. The gap between what the research shows and what consumers experience is largely a delivery problem.",
            "Nanoemulsion technology addresses this by encapsulating active compounds in lipid-based nanoparticles that increase absorption across the intestinal epithelium. The effect is not to make endogenous activation equivalent to pharmaceutical intervention, but to ensure that the compounds known to stimulate GLP-1 production actually reach their target pathways at effective concentrations.",
            "When delivery is optimized, the endogenous activation thesis becomes testable in a way it was not with standard supplement formats. The compounds have published evidence. The pathways are well-characterized. The remaining variable was whether they could be delivered effectively. That is the problem nanoemulsion solves.",
          ],
        },
      ]),
      JSON.stringify(["natural-dpp4-inhibition", "nanoemulsion-vs-capsules"]),
    ],
  });

  // ── FAQs ──────────────────────────────────────────────────────

  const faqSql = "INSERT INTO faqs (category, question, answer, sort_order) VALUES (?, ?, ?, ?)";

  const faqData: [string, string, string][] = [
    ["GLP-1 Basics", "What is GLP-1 and why does it matter for weight management?", "GLP-1 (glucagon-like peptide-1) is an incretin hormone produced naturally in your gut after eating. It signals your brain to reduce appetite, slows gastric emptying so you feel full longer, and stimulates insulin secretion to regulate blood sugar. GLP-1 is the same hormone targeted by prescription drugs like Ozempic and Wegovy. The difference is how you increase it: those drugs inject synthetic versions, while natural approaches aim to boost your body's own production."],
    ["GLP-1 Basics", "Can you increase GLP-1 naturally without injections?", "Yes. Your intestinal L-cells produce GLP-1 in response to specific nutrients and compounds. Research shows that AMPK pathway activation stimulates GLP-1 secretion from L-cells. GPR120 receptor signaling on the same cells triggers additional incretin release. Insulin receptor sensitization supports glucose-dependent GLP-1 output. The challenge has always been bioavailability \u2014 getting these compounds to their target pathways at effective concentrations through oral delivery."],
    ["GLP-1 Basics", "What is DPP-4 and how does it affect GLP-1 levels?", "DPP-4 (dipeptidyl peptidase-4) is an enzyme that rapidly degrades GLP-1 after it's produced. Natural GLP-1 has a half-life of about 2 minutes because DPP-4 breaks it down almost immediately. This is why pharmaceutical GLP-1 drugs use synthetic analogs that resist DPP-4 degradation. An alternative approach is to inhibit DPP-4 itself, extending the window your naturally produced GLP-1 remains active. This is one of the three mechanisms in the Slim SHOT formula."],
    ["GLP-1 Basics", "What is the difference between endogenous and exogenous GLP-1?", "Endogenous GLP-1 is what your body produces on its own, primarily from L-cells in the small intestine. Exogenous GLP-1 is introduced from outside the body, like the synthetic semaglutide in Ozempic. Endogenous activation works with your body's existing feedback loops and dose-response mechanisms. Exogenous injection overrides those loops with pharmaceutical-grade concentrations, which is why it's more powerful but also carries more side effects."],
    ["Nanoemulsion Technology", "What is a nanoemulsion and how does it improve supplement absorption?", "A nanoemulsion is a delivery system that encapsulates active compounds in lipid-based nanoparticles, typically 20-200 nanometers in diameter. This dramatically increases surface area, protects compounds from enzymatic degradation in the GI tract, and enhances cellular uptake through improved membrane permeability. Most oral supplements have bioavailability problems \u2014 the compounds degrade before reaching their target pathways. Nanoemulsion technology solves this by creating a stable, absorbable carrier for each active compound."],
    ["Nanoemulsion Technology", "Why do most oral supplements have low bioavailability?", "Three main reasons. First, stomach acid and digestive enzymes degrade many compounds before they can be absorbed. Second, the intestinal lining is selective about what it lets through \u2014 large or hydrophobic molecules often can't cross efficiently. Third, first-pass metabolism in the liver further reduces the amount of active compound that reaches systemic circulation. A compound can show strong effects in a lab study but deliver almost nothing when swallowed as a standard capsule or tablet."],
    ["Nanoemulsion Technology", "How is nanoemulsion different from liposomal delivery?", "Both use lipid-based carriers, but the structures differ. Liposomes are spherical vesicles with a water-filled core surrounded by a lipid bilayer. Nanoemulsions are thermodynamically stable droplets of oil dispersed in water (or vice versa) stabilized by surfactants. Nanoemulsions generally offer better physical stability, longer shelf life, and more consistent particle size distribution. For the specific compounds in the Slim SHOT formula, nanoemulsion was selected for superior bioavailability and manufacturing reproducibility."],
    ["Formulation & Science", "How does AMPK activation stimulate GLP-1 production?", "AMP-activated protein kinase (AMPK) is a key metabolic sensor in intestinal L-cells. When activated, it stimulates the secretion of GLP-1. Multiple randomized controlled trials have demonstrated significant increases in postprandial GLP-1 levels through AMPK-mediated pathways. AMPK activation also has independent effects on glucose metabolism, lipid profiles, and insulin sensitivity. The mechanism of action on GLP-1 has been well characterized in recent clinical research."],
    ["Formulation & Science", "What role does GPR120 receptor activation play in GLP-1 signaling?", "GPR120 (also called FFAR4) is a free fatty acid receptor expressed on intestinal L-cells. When GPR120 is activated, it triggers intracellular signaling cascades that result in GLP-1 secretion. This is a distinct pathway from AMPK activation, which is why the two mechanisms work synergistically. GPR120-mediated signaling also supports anti-inflammatory effects and healthy lipid metabolism."],
    ["Formulation & Science", "How does insulin receptor sensitization contribute to the formula?", "Insulin receptor sensitization enhances the binding of insulin to its receptor, facilitating glucose uptake into cells via GLUT4 translocation. This complements direct GLP-1 activation through AMPK and GPR120 pathways by improving the downstream metabolic response. The compounds used for this mechanism hold GRAS status and have extensive clinical literature supporting their role in glucose metabolism."],
    ["Formulation & Science", "How many metabolic pathways does the formula target?", "Thirteen distinct pathways across three primary mechanisms: GLP-1 and GIP activation, DPP-4 enzyme inhibition, and complementary metabolic support including insulin sensitivity enhancement, appetite regulation via the gut-brain axis, and AMPK-mediated lipid metabolism. The formula is designed as an integrated system rather than a single-mechanism product. Each compound contributes to multiple pathways, and the combinations produce synergistic effects documented in published research."],
    ["Safety & Quality", "Are natural GLP-1 supplements safe?", "All compounds in the Slim SHOT formula hold GRAS (Generally Recognized as Safe) status and have extensive safety profiles in clinical literature. The key safety consideration is drug interactions \u2014 certain active compounds can interact with medications metabolized by CYP enzymes and blood sugar-lowering drugs. Anyone on prescription medication should consult their healthcare provider before starting any GLP-1-targeting nutraceutical."],
    ["Safety & Quality", "What does GRAS status mean?", "GRAS stands for Generally Recognized as Safe. It's an FDA designation indicating that a substance is generally recognized, among qualified experts, as safe under its intended conditions of use. GRAS status requires substantial evidence of safety through scientific procedures or, for substances used in food before 1958, through experience based on common use. All compounds in Slim SHOT hold GRAS status at the dosages used in the formula."],
    ["Safety & Quality", "What is cGMP manufacturing and why does it matter?", "cGMP stands for current Good Manufacturing Practice. These are FDA-enforced regulations that ensure products are consistently produced and controlled according to quality standards. cGMP covers everything from facility design and equipment maintenance to raw material testing, production processes, and final product testing. Manufacturing in cGMP-certified facilities means every batch of Slim SHOT meets the same purity, potency, and composition specifications."],
    ["Comparison & Context", "How does Slim SHOT compare to prescription GLP-1 drugs like Ozempic?", "They target the same biological pathway through fundamentally different mechanisms. Ozempic (semaglutide) injects a synthetic peptide that mimics GLP-1 and resists DPP-4 degradation, delivering sustained supraphysiological GLP-1 receptor activation. Slim SHOT amplifies your body's own GLP-1 production and inhibits DPP-4 to extend its natural half-life. The pharmaceutical approach is more potent. The endogenous approach works within your body's existing feedback loops with a different risk-benefit profile. They are not equivalent and Slim SHOT is not a replacement for prescribed medication."],
    ["Comparison & Context", "Why is Slim SHOT a liquid instead of a capsule or pill?", "The nanoemulsion delivery system requires a liquid format to maintain the integrity and stability of the lipid-based nanoparticles. Compressing a nanoemulsion into a dry capsule or tablet would destroy the nanoparticle structure that makes it effective. The liquid format also allows for faster absorption since there's no dissolution step \u2014 the active compounds are already in a bioavailable form when they reach the intestinal lining."],
    ["Comparison & Context", "What is the difference between a supplement and a drug?", "Under U.S. law, dietary supplements are regulated under the Dietary Supplement Health and Education Act (DSHEA) and are classified as food products, not drugs. Supplements cannot claim to diagnose, treat, cure, or prevent any disease. They do not require pre-market FDA approval, though they must contain compounds that are safe and the products must be manufactured according to cGMP standards. Drugs undergo a different regulatory pathway including clinical trials and FDA pre-market approval. Slim SHOT is a dietary supplement."],
  ];

  for (let i = 0; i < faqData.length; i++) {
    const [cat, q, a] = faqData[i];
    await db.execute({ sql: faqSql, args: [cat, q, a, i] });
  }

  // ── Products ──────────────────────────────────────────────────

  const productSql = "INSERT INTO products (slug, name, tagline, price, description, features, status, launch_date, sort_order) VALUES (?, ?, ?, ?, ?, ?, ?, ?, ?)";

  await db.execute({
    sql: productSql,
    args: [
      "slim-shot",
      "Slim SHOT",
      "Daily liquid nanoemulsion. Our flagship GLP-1 activator.",
      "$149/mo",
      "A patent-pending drinkable nanoemulsion that activates your body's natural GLP-1 and GIP production.",
      JSON.stringify([
        "Patent-pending nanoemulsion delivery",
        "13 complementary metabolic pathways",
        "GRAS-certified compounds",
        "cGMP manufactured",
        "Third-party tested",
      ]),
      "available",
      null,
      0,
    ],
  });

  await db.execute({
    sql: productSql,
    args: [
      "thermogenic",
      "Thermogenic",
      "GLP-1 activation meets clean energy. Ready-to-drink.",
      null,
      "GLP-1 activation meets clean energy in a ready-to-drink format.",
      JSON.stringify([]),
      "coming-soon",
      "2026",
      1,
    ],
  });

  await db.execute({
    sql: productSql,
    args: [
      "glp1-sweetener",
      "GLP-1 Sweetener",
      "Zero-calorie sweetener that supports incretin response.",
      null,
      "Zero-calorie sweetener with built-in incretin pathway support.",
      JSON.stringify([]),
      "coming-soon",
      "2026",
      2,
    ],
  });

  await db.execute({
    sql: productSql,
    args: [
      "glp1-protein-powder",
      "GLP-1 Protein Powder",
      "30g protein per serving with built-in GLP-1 support.",
      null,
      "High-protein formula with integrated GLP-1 pathway activation.",
      JSON.stringify([]),
      "coming-soon",
      "2027",
      3,
    ],
  });

  // ── Audience Personas ────────────────────────────────────────

  const personaSql = `INSERT INTO audience_personas (name, slug, description, demographics, goals, pain_points, communication_style, objections, channels, is_default) VALUES (?, ?, ?, ?, ?, ?, ?, ?, ?, ?)`;

  await db.execute({
    sql: personaSql,
    args: [
      "The Needle-Averse Consumer",
      "needle-averse-consumer",
      "Interested in GLP-1 results but unwilling to self-inject. Has researched Ozempic and Wegovy. Wants a non-pharmaceutical alternative that works through the same biological pathway.",
      "Age 35-55. Predominantly female. Household income $75K-$150K. Health-conscious but not biohacker-level. Gets information from social media, podcasts, and their primary care doctor. Has tried at least two weight management approaches in the past three years.",
      "Lose 15-30 lbs without injections or harsh side effects. Feel in control of the process. Find something backed by real science, not supplement-aisle noise. Avoid the medical system for weight management if possible.",
      "Overwhelmed by conflicting information about GLP-1 drugs. Skeptical of supplements after past disappointments. Worried about side effects reported with prescription GLP-1 drugs (nausea, gastroparesis). Frustrated by the cost of Ozempic without insurance. Doesn't trust 'miracle cure' marketing.",
      "Plain language over clinical terminology. Lead with mechanism of action, not promises. She responds to specificity and honesty about what the product is and isn't. Testimonials and before/after narratives carry weight. Prefers paragraph-form content over bullet-point marketing. Distrusts urgency tactics.",
      "How is this different from every other supplement that doesn't work? If it really worked, wouldn't it need a prescription? What about long-term safety? Why should I trust a company I've never heard of?",
      JSON.stringify(["instagram", "facebook", "email", "podcast-ads"]),
      1,
    ],
  });

  await db.execute({
    sql: personaSql,
    args: [
      "The Cost-Conscious Buyer",
      "cost-conscious-buyer",
      "Wants GLP-1 pathway support but can't justify $800-$1,600/month for prescription drugs. Price is the primary decision driver. Needs to feel the value proposition is real before committing.",
      "Age 30-50. Mixed gender. Household income $50K-$100K. May or may not have insurance that covers GLP-1 drugs. Has priced out Ozempic or been told by their doctor it's not covered. Comparison shops aggressively.",
      "Find an affordable alternative to prescription GLP-1 drugs. Understand exactly what they're paying for and why. Feel confident the money is well spent. See results within the first 30-60 days to justify continued purchase.",
      "Sticker shock from prescription GLP-1 drug pricing. Insurance denials or high copays. Skepticism that anything at $149/mo can work if the 'real' drugs cost 10x more. Has been burned by subscription traps and auto-ship programs. Worries about ongoing cost commitment.",
      "Lead with price comparison and value framing. Be transparent about what $149/mo includes. Data and mechanism of action matter but cost-per-result is the deciding factor. Wants to see the math. Responds to money-back guarantees and flexible subscription terms. Short, direct copy. No fluff.",
      "If it's this much cheaper, it probably doesn't work as well. What's the catch with the subscription? Can I cancel anytime? Why can't I just buy the individual ingredients for less?",
      JSON.stringify(["google-search", "email", "comparison-sites", "facebook"]),
      0,
    ],
  });

  await db.execute({
    sql: personaSql,
    args: [
      "The Performance Optimizer",
      "performance-optimizer",
      "Not trying to lose weight. Interested in metabolic efficiency, body composition, and longevity. Already trains and eats well. Sees GLP-1 modulation as a performance input, not a medical intervention.",
      "Age 28-45. Predominantly male. Household income $100K+. Reads Huberman, Attia, Rhonda Patrick. Uses a CGM or has considered one. Tracks macros, sleep, and HRV. Supplements strategically, not impulsively. Works in tech, finance, or a knowledge-work field.",
      "Optimize metabolic flexibility and insulin sensitivity. Maintain or improve body composition without muscle loss. Add a scientifically grounded tool to an existing optimization stack. Understand the mechanism at a deeper level than marketing copy provides.",
      "Concerned about muscle wasting reported with high-dose synthetic GLP-1 agonists. Wants to know the specific compounds and their published research. Frustrated by supplement marketing that talks down to him. Skeptical of anything that doesn't disclose its full ingredient profile and dosing.",
      "Technical language is expected and preferred. Cite specific studies or at least name the compounds and pathways. He'll verify claims independently. Long-form scientific content performs better than short social copy. Respects intellectual honesty about limitations. Wants to understand the formula architecture, not just the benefits.",
      "Where's the peer-reviewed data? What are the specific compounds and doses? How does this interact with my existing stack? Is the effect magnitude even worth it if I'm already metabolically healthy? Why nanoemulsion over other delivery methods?",
      JSON.stringify(["twitter-x", "podcasts", "linkedin", "longevity-forums", "email"]),
      0,
    ],
  });

  await db.execute({
    sql: personaSql,
    args: [
      "The Side Effects Refugee",
      "side-effects-refugee",
      "Started a prescription GLP-1 drug and quit because the side effects were unbearable. Still wants the metabolic benefits. Looking for something that works through the same pathway without the nausea, vomiting, or gastroparesis risk.",
      "Age 30-55. Skews female but not exclusively. Household income varies widely. Has an existing relationship with a prescribing doctor. Tried Ozempic, Wegovy, or Mounjaro for 2-12 weeks before discontinuing. May have lost some weight before quitting. Active on Reddit GLP-1 communities and Facebook groups where side effect stories circulate.",
      "Find a way to keep the appetite regulation and metabolic benefits without the GI distress. Avoid going back to the injection. Feel normal after meals again. Lose weight at a sustainable pace even if it's slower than the drugs. Not get talked into trying the injection 'one more time' at a lower dose.",
      "Traumatized by the nausea, vomiting, or stomach paralysis they experienced on Rx GLP-1 drugs. Feels dismissed by doctors who say side effects are 'manageable' or 'temporary.' Frustrated that they spent hundreds of dollars on something they couldn't tolerate. Worried that anything targeting GLP-1 will trigger the same reaction. Trust in the pharmaceutical approach is broken.",
      "Empathy first, science second. She needs to feel understood before she'll read the mechanism of action. Personal stories from others who switched carry more weight than clinical data. Be explicit about what Slim SHOT is NOT: it is not a lower dose of the same thing. Explain the endogenous vs. exogenous distinction in plain language. Avoid anything that sounds like minimizing her experience.",
      "Won't this just give me the same nausea? My doctor says nothing else works as well as semaglutide. How can something that targets the same pathway not have the same side effects? I already spent money on something that didn't work out. Why would this be different?",
      JSON.stringify(["facebook-groups", "reddit", "instagram", "email", "google-search"]),
      0,
    ],
  });

  await db.execute({
    sql: personaSql,
    args: [
      "The In-Between",
      "the-in-between",
      "BMI 26-29. Not diabetic. Not clinically obese. Metabolically at risk but locked out of the prescription GLP-1 pathway because they don't meet diagnostic thresholds. Their doctor says they're fine. They know they're not.",
      "Age 35-50. Mixed gender, slight female skew. Household income $60K-$120K. Has had bloodwork that showed borderline fasting glucose, elevated triglycerides, or early insulin resistance markers. BMI doesn't qualify for GLP-1 drug coverage. Doctor may have mentioned 'lifestyle changes' without specifics. Educated enough to read their own lab results and know the trajectory.",
      "Get ahead of a metabolic problem before it becomes a diagnosis. Find a tool that takes their situation seriously instead of telling them to eat less and exercise more. Feel proactive about their health without needing to be sick first. Access GLP-1 pathway support without gaming the insurance system or paying cash prices for off-label prescriptions.",
      "Feels invisible to the healthcare system. Too healthy for medication, too at-risk to do nothing. Frustrated by the BMI gatekeeping around GLP-1 prescriptions. Knows that waiting for a diabetes or obesity diagnosis means waiting for the problem to get worse. Has researched compounded semaglutide and telehealth prescribers but feels uneasy about the gray market. Tired of generic 'eat better, move more' advice.",
      "Validate the frustration without being anti-medical-establishment. This person respects their doctor but feels underserved by the current diagnostic framework. Lead with the metabolic science: insulin resistance, fasting glucose trends, the continuum between healthy and diagnosable. Position Slim SHOT as the proactive intervention the system doesn't offer yet. Data-forward but accessible. No condescension.",
      "If I'm not diabetic or obese, do I even need this? My doctor says my numbers are 'borderline normal.' Is this just for people who want to lose weight? How do I know this is doing anything if I don't have dramatic weight to lose? Am I just being anxious about nothing?",
      JSON.stringify(["google-search", "health-podcasts", "email", "instagram", "linkedin"]),
      0,
    ],
  });

  // ── Site Settings ─────────────────────────────────────────────

  const settingSql = "INSERT INTO site_settings (key, value) VALUES (?, ?)";

  await db.execute({ sql: settingSql, args: ["site_name", "NutraGLP"] });
  await db.execute({ sql: settingSql, args: ["site_tagline", "Natural GLP-1 Activation"] });
  await db.execute({
    sql: settingSql,
    args: [
      "fda_disclaimer",
      "*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. NutraGLP is a dietary supplement. Consult your healthcare provider before starting any new supplement regimen.",
    ],
  });
  await db.execute({
    sql: settingSql,
    args: [
      "supplement_disclaimer",
      "NutraGLP is a dietary supplement, not a drug. It is not intended to diagnose, treat, cure, or prevent any disease.",
    ],
  });
  await db.execute({ sql: settingSql, args: ["linkedin", "https://www.linkedin.com/company/nutraglp"] });
  await db.execute({ sql: settingSql, args: ["instagram", "https://www.instagram.com/nutraglp"] });
  await db.execute({ sql: settingSql, args: ["twitter", "https://x.com/nutraglp"] });
  await db.execute({ sql: settingSql, args: ["copyright", "\u00a9 {year} NutraGLP. All rights reserved."] });
  await db.execute({ sql: settingSql, args: ["admin_password", "get-content-foundry-2026"] });

  // Popup / Email Capture defaults
  await db.execute({ sql: settingSql, args: ["popup_enabled", "true"] });
  await db.execute({ sql: settingSql, args: ["popup_delay_seconds", "12"] });
  await db.execute({ sql: settingSql, args: ["popup_scroll_threshold", "55"] });
  await db.execute({ sql: settingSql, args: ["popup_heading", "Get on the list before we launch."] });
  await db.execute({ sql: settingSql, args: ["popup_subheading", "Slim SHOT ships soon. Early subscribers get first access and launch pricing."] });
  await db.execute({ sql: settingSql, args: ["popup_cta_text", "Join Early Access"] });
  await db.execute({ sql: settingSql, args: ["popup_show_phone", "true"] });
  await db.execute({ sql: settingSql, args: ["popup_show_sms_optin", "true"] });

  console.log("Seed complete.");
}

// Run if called directly
seed();
